Danaher forecasts 3%-4% 2026 core revenue growth and raises adjusted EPS to $8.45-$8.60 following Masimo close
Seeking Alpha ·
Earnings Call Insights: Danaher (DHR) Q2 2026 "We delivered a solid second quarter with better-than-expected revenue, earnings and cash flow" (President, CEO & Director Rainer Blair), adding, "Our Life Sciences businesses delivered their strongest quarter in several years" and "the earlier-than-expected close of Masimo enables us to
AI 시장 분석
Danaher (DHR) projected a 3-4% core revenue growth rate for 2026 and raised its adjusted EPS to $8.45-$8.60, driven by the completion of the Masimo acquisition. CEO Rainer Blair stated that the life sciences division achieved its best performance in years. This strong performance is spreading positive investment sentiment across the healthcare and life sciences sectors.
상승 영향
- Biotech — Danaher's strength in the life sciences segment and the completed Masimo acquisition increase earnings growth visibility, which is positive for the biotech and life sciences equipment industry.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 50% · Bearish (Short) 50%
240 participants
Related News
- U.S. company to build Ukrainian drone boats amid Pentagon demand: WSJ
- Calix forecasts Q3 2026 revenue of $301M-$307M while targeting 2026 growth at the higher end of 15%-20%
- Alphabet Launches Three Gemini Models Amid Mounting AI Competition
- What TSMC's capex surge could mean
- Tesla Expands Robotaxi Service in Florida
- OpenAI's latest ChatGPT program targets small business market
